Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 1
2010 3
2011 3
2012 3
2013 3
2014 4
2015 2
2016 5
2017 8
2018 2
2019 6
2020 12
2021 9
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, Teng M, Liang Y, Hatcher J, Li Z, Manz TD, Groendyke B, Hu W, Nam Y, Sengupta S, Cho H, Shin I, Agius MP, Ghobrial IM, Ma MW, Che J, Buhrlage SJ, Sim T, Gray NS, Fischer ES. Donovan KA, et al. Among authors: buhrlage sj. Cell. 2020 Dec 10;183(6):1714-1731.e10. doi: 10.1016/j.cell.2020.10.038. Epub 2020 Dec 3. Cell. 2020. PMID: 33275901 Free article.
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Schauer NJ, Magin RS, Liu X, Doherty LM, Buhrlage SJ. Schauer NJ, et al. Among authors: buhrlage sj. J Med Chem. 2020 Mar 26;63(6):2731-2750. doi: 10.1021/acs.jmedchem.9b01138. Epub 2019 Nov 20. J Med Chem. 2020. PMID: 31682427 Review.
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.
Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage SJ, DeNicola GM, Kaelin WG Jr, Brugge JS. Harris IS, et al. Among authors: buhrlage sj. Cell Metab. 2019 May 7;29(5):1166-1181.e6. doi: 10.1016/j.cmet.2019.01.020. Epub 2019 Feb 21. Cell Metab. 2019. PMID: 30799286 Free PMC article.
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg E, Meng C, Case AE, Sattler M, Tiv HL, Gokhale PC, Buhrlage SJ, Liu X, Yang J, Wang J, Gray N, Stone RM, Adamia S, Dubreuil P, Letard S, Griffin JD. Weisberg E, et al. Among authors: buhrlage sj. Br J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15. Br J Haematol. 2019. PMID: 31309543 Free PMC article.
Chemoproteomic methods for covalent drug discovery.
Chan WC, Sharifzadeh S, Buhrlage SJ, Marto JA. Chan WC, et al. Among authors: buhrlage sj. Chem Soc Rev. 2021 Aug 2;50(15):8361-8381. doi: 10.1039/d1cs00231g. Chem Soc Rev. 2021. PMID: 34143170 Review.
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Weisberg E, et al. Among authors: buhrlage sj. Pharm Res. 2020 Aug 10;37(9):167. doi: 10.1007/s11095-020-02851-7. Pharm Res. 2020. PMID: 32778962 Free PMC article. Review.
Proteomics-Based Identification of DUB Substrates Using Selective Inhibitors.
Bushman JW, Donovan KA, Schauer NJ, Liu X, Hu W, Varca AC, Buhrlage SJ, Fischer ES. Bushman JW, et al. Among authors: buhrlage sj. Cell Chem Biol. 2021 Jan 21;28(1):78-87.e3. doi: 10.1016/j.chembiol.2020.09.005. Epub 2020 Oct 1. Cell Chem Biol. 2021. PMID: 33007217 Free PMC article.
Developing irreversible inhibitors of the protein kinase cysteinome.
Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Liu Q, et al. Among authors: buhrlage sj. Chem Biol. 2013 Feb 21;20(2):146-59. doi: 10.1016/j.chembiol.2012.12.006. Chem Biol. 2013. PMID: 23438744 Free PMC article. Review.
56 results